A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).
Publication
, Conference
Stinchcombe, TE; Janne, PA; Wang, X; Bertino, EM; Weiss, JM; Bazhenova, L; Gu, L; Lau, CJ; Paweletz, CP; Jaslowski, AJ; Gerstner, GJ ...
Published in: Ann Oncol
October 2018
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2018
Volume
29 Suppl 8
Start / End Page
viii522
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Stinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L., … Vokes, E. E. (2018). A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). In Ann Oncol (Vol. 29 Suppl 8, p. viii522). England. https://doi.org/10.1093/annonc/mdy292.066
Stinchcombe, T. E., P. A. Janne, X. Wang, E. M. Bertino, J. M. Weiss, L. Bazhenova, L. Gu, et al. “A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).” In Ann Oncol, 29 Suppl 8:viii522, 2018. https://doi.org/10.1093/annonc/mdy292.066.
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, et al. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). In: Ann Oncol. 2018. p. viii522.
Stinchcombe, T. E., et al. “A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC).” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii522. Pubmed, doi:10.1093/annonc/mdy292.066.
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, Gu L, Lau CJ, Paweletz CP, Jaslowski AJ, Gerstner GJ, Baggstrom MQ, Graziano SL, Bearden J, Vokes EE. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2018. p. viii522.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2018
Volume
29 Suppl 8
Start / End Page
viii522
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis